Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.  This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  The initiation of this Phase I clinical trial triggered a $10 million milestone payment from GSK.

"With the successful conclusion of the discovery phase of our GSK alliance, we are intensifying and expanding our efforts in our other ongoing programs that are entirely outside the GSK alliance," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists. In addition, we are advancing programs in liver and kidney disease and in the next generation of medicines for inflammatory bowel disease, all of which offer vast opportunities in largely unmet medical needs."

About ChemR23/CCX832

The ligand for ChemR23, chemerin, is a widely expressed protein that circulates in human plasma in an inactive state and becomes biologically activated in inflammatory settings. There is building evidence that suggests chemerin may serve as a biological alarm signal that, under conditions of tissue injury, recruits ChemR23-expressing immune cells. Diseases such as psoriasis are also associated with elevated levels of activated chemerin. In preclinical studies, CCX832 has demonstrated the ability to successfully block
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... -- This report analyzes the worldwide markets for Medical ... provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts are provided ... historic analysis is provided for these markets. Market data ... Company profiles are primarily based on public domain information ...
(Date:4/20/2015)... April 20, 2015  SillaJen, Inc., a private ... oncolytic immunotherapy products for cancer, today announced an ... Annual Meeting of the American Association for Cancer ... adapted version of its lead product candidate, Pexa-Vec ... an oncolytic immunotherapy designed to 1) rapidly de-bulk ...
(Date:4/20/2015)... EXTON, Pa. , April 20, 2015 The ... leader in pharmacokinetic testing of drugs and safety testing of ... , will present at this week,s workshop " Drug Transporters ... Baltimore, MD . The title of Dr. ... Transporters," part of a session entitled "Transporter Tools of the ...
Breaking Medicine Technology:World Medical Equipment Rental and Leasing Industry 2World Medical Equipment Rental and Leasing Industry 3World Medical Equipment Rental and Leasing Industry 4World Medical Equipment Rental and Leasing Industry 5World Medical Equipment Rental and Leasing Industry 6World Medical Equipment Rental and Leasing Industry 7SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 2SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 3Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2
... YORK, May 12, 2011 Reportlinker.com announces ... available in its catalogue: ... 2017 http://www.reportlinker.com/p0493115/Asia-Pacific-Hospital-Supplies-Market-Outlook-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Outlook to 2017 Summary ...
... Korea, May 11, 2011 CrystalGenomics, Inc., a biopharmaceutical ... that the draft Clinical Study Report (CSR) from CG400549,s ... been received. CG400549 is a potential first-in-class ... a critical enzyme in generating bacterial membrane and has ...
Cached Medicine Technology:Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 2Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 3Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 4Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 5Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 6Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 7Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 8Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 9Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 10Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 11Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 12Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 13Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 14Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017 15CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study 2
(Date:4/20/2015)... April 20, 2015 Saint Joseph Regional Medical ... Top Health Systems by Truven Health Analytics, a leading provider ... of healthcare. SJRMC has been recognized by Truven Health Analytics ... past four years. , According to Truven Health Analytics' ... Systems, in matchups with their peers, set the standard for ...
(Date:4/20/2015)... At the famous Avalon Hollywood on April 8th, ... Lounge, with Choices Recovery as the premier sponsor. Organizer ... placement in TV and film, gathered some of the ... goods and services for this daylong event. , ... Celebrity Interview Lounge, speaking with many of the notable ...
(Date:4/20/2015)... 20, 2015 Novatus, a leading ... expanded its service level to the growing European ... Amsterdam and Paris. After a rigorous review ... levels of resilience, security and operational expertise, and ... for Novatus as we expand our footprint and ...
(Date:4/20/2015)... FL (PRWEB) April 20, 2015 Florida ... to receive three prestigious awards from Select Medical, during ... Tampa on Friday, April 10th. Chief Operating Officer, Debi ... stable leadership. She was one of six recipients out ... the Stu Dinney Humanitarian Award for the contributions to ...
(Date:4/20/2015)... April 20, 2015 Today the ... Cancer Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer ... Dream Team will focus on “DNA Repair Therapies ... have identified DNA repair as a common weakness ... prevention and early detection of ovarian cancer by ...
Breaking Medicine News(10 mins):Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 2Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 3Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Novatus Expands into European Data Centers 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4
... ... New York personal injury attorney, David Perecman. , ... New York, NY (PRWEB) July 14, 2009 -- Three workers, including a ... accident at a privately operated waste transfer plant in Jamaica, Queens. All three apparently ...
... , , LAKEWOOD, Colo., July 14 ... has been named to the Fortune Small Business Magazine,s (FSB) annual list ... Every year the editors of FSB analyze public companies with annual revenues ... revenues and stock performance over the past three years. This is ...
... July 14 The A.M. McGregor Group, a direct provider and benefactor ... House - a 25-bed nursing facility atop Cedar Hill near University Circle ... The facility, in the City of Cleveland on the boundary of ... in early fall as McGregor at Overlook. , ...
... Irvine, Calif., July 14, 2009 A drug similar to ... and psoriasis has been found to rescue memory in mice ... offers hope that a new treatment may be on the ... leading cause of elderly dementia afflicting more than 5 million ...
... ARBOR, Mich., July 14 As the recent decline in ... care search engine is making it even easier for families to ... launch of their ElderCare Library and ... http://www.thecaringspace.com ) provides an industry-leading set of resources that empowers its ...
... , , , HULL, ... (NYSE: SNN ) announced that the UK Court of Appeal ... patent EP 0 626 720 that is licensed to Kinetic Concepts, Inc. (NYSE: ... & Nephew,s RENASYS(TM)-F NPWT system has been lifted. , ...
Cached Medicine News:Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 3Health News:Fortune Names Mesa Laboratories as one of America's Fastest Growing Small Public Companies 2Health News:The McGregor Group to Reopen Overlook House in Cleveland as a New Nursing Facility 2Health News:Drug rescues memory lost to Alzheimer's disease 2Health News:Leading Senior Care Destination TheCaringSpace.com Launches ElderCare Library and Care Community 2Health News:UK Court of Appeal Rules in Smith & Nephew's Favour 2Health News:UK Court of Appeal Rules in Smith & Nephew's Favour 3
Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
96-well Silicone Compression Mat, Bulk...
Silicone Compression Mat, Bulk...
96-well Silicone Expansion Mat, Bulk...
Medicine Products: